Lecanemab injection | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Company: Eisai Inc.
Medicine type: Biologic
Therapeutic area: Neurology
Indications recorded in the public source: Treatment of mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's dementia.
Indication source and scope: Source date(s): 2025, 2026. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label.
Prescribing-information limitations: Complete official prescribing information obtained. The available full label is from an overseas jurisdiction; a complete current Chinese label remains unavailable. Chinese indications are supported separately by Chinese sources.
China availability status: Historical Chinese approval verified; current continuous market availability has not been checked for every product.
Overseas status: Japan, United Kingdom: local approval / launch announcements and official price sources obtained. Indications and dates are specified in each price record; other markets not exhaustively reviewed.
Insurance classification: Commercial insurance list only; not included in basic insurance
Insurance edition: 2025 edition; effective 1 January 2026
Insurance restrictions: Inclusion in the commercial insurance drug list does not imply payment by the basic medical insurance fund. Commercial insurance coverage depends on the individual policy.
Insurance verification notes: Exact match in the commercial insurance list; the basic insurance notice excludes payment.

Sources

Open the interactive record, public price references and discussions